HOME >> BIOLOGY >> NEWS
Cyclacel's biomarker technology shows that CYC202 induces cancer cells to commit suicide

Washington, DC, 14 July 2003 - Cyclacel Limited, the UK-based biopharmaceutical company, reported today that it demonstrated through state-of-the-art biomarker technology that CYC202 (R-roscovitine), its lead CDK inhibitor drug candidate, appears to induce cancer cell suicide or apoptosis in patients receiving the drug. Details of the biomarker data obtained with CYC202 were reported today at an oral presentation at the American Association for Cancer Research (AACR) annual meeting taking place here.

Biomarker technology is used to understand the molecular mechanism of action of novel drugs in humans, provide insights into their pharmacological properties, measure their biological effect (e.g. induce cancer cells to commit suicide) and determine susceptibility or resistance to the treatment. In the long-term biomarker analysis of tumour blood and tissues may allow selective treatment with CYC202 of those patients identified as likely to benefit from the drug based on the specific genetic profile of their tumour.

Biomarker analysis of blood samples from patients with cancer treated with CYC202 demonstrated that 54% (14 of 26 analysed) tested positive for cancer cell death or apoptosis following single agent treatment with the drug. In addition, seven CYC202 Phase I patients with various tumours, including pancreas and lung cancer, experienced long lasting tumour stabilisation. These patients received CYC202 capsules taken by mouth after exhausting other treatment options. CYC202 is presently being tested in two international, multicentre Phase IIa clinical trials for the treatment of breast and lung cancer in combination with standard chemotherapy.

Cyclacel's Biomarker Team used a novel assay technique to calculate the extent by which cancer cells are committing suicide (or apoptotic index) in different patients on the drug. An advantage of this test is that it measures cellular material released into the circulation by dying or dead cance
'"/>

Contact: Robert Gottlieb
robert.gottlieb@fkhealth.com
617-577-8110
Feinstein Kean Healthcare
14-Jul-2003


Page: 1 2 3

Related biology news :

1. New drug target and biomarker for advanced childhood cancer discovered
2. Protein biomarkers accurately and quickly diagnose ALS, find Pittsburgh researchers
3. Ki-67 biomarker a strong predictor of outcome for prostate cancer patients
4. Illinois study seeking biomarkers of canine diabetes, other diseases
5. Oral contraceptives increase C-reactive protein, an infIammatory biomarker
6. Promising biomarker for melanoma is identified
7. UC Davis M.I.N.D. Institute launches new program to identify biomarkers for autism and other disorders
8. Yale digital diagnostic technology is basis of new company, HistoRx Inc.
9. AACR applauds NCI initiative on nanotechnology
10. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
11. New imaging technology at Joslin shown to detect early signs of type 1 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... , ... August 19, 2020 , ... ... premier conference and expo uniting life science, data science, informatics and IT leaders ... , “In this period of uncertainty and change, Bio-IT takes the leadership role ...
(Date:8/7/2020)... SAN FRANCISCO (PRWEB) , ... August 06, 2020 ... ... the life sciences industry, is pleased to announce that Eric Chen and Jessica ... Vice President of Product Management & Strategy, respectively. , Eric Chen heads development ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense ... to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... “We are ... Third Wave Bioactives. “It’s the only technology of its kind on the market and ... of onions with the protective capacity of traditional cultured ingredients, creating a natural way ...
(Date:7/18/2020)... ... 17, 2020 , ... dicentra , a leading Contract ... industries, is pleased to announce that Charles Galea has joined its clinical trials ... is an accomplished and results-driven sales executive with over 10 years of expertise ...
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
(Date:7/10/2020)... ... 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will ... SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the ...
Breaking Biology Technology:
Cached News: